1.	Allogenic Stem Cell Transplantation (SCT) With Non-Myeloablative Conditioning in Patients With Relapse Non-Hodgkin's Lymphoma (NHL) Phase: Phase II Type: Treatment Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: GELTAMO-Z-RIC-Allo, EuDRACT nº:2007-003302-10, NCT00644371
2.	ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®) Phase: Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: ZAR2007, NCT00662948
3.	Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment Phase: Phase I Type: Treatment Status: Active Age: 65 and over Sponsor: Other Protocol IDs: SAKK 37/05, SWS-SAKK-37/05, EU-20648, SPRI-SWS-SAKK-37/05, CDR0000511915, NCT00392691
4.	Zevalin Post-marketing Surveillance in Japan Phase: No phase specified Type: Natural history/Epidemiology Status: Active Age: Not specified Sponsor: Pharmaceutical / Industry Protocol IDs: 15042, NCT01448928